Moray J. Campbell

This study identifies ONECUT2 as a master transcription factor that drives resistance in prostate cancer through multiple mechanisms, including activation of neuroendocrine and adenocarcinoma variants, and shows that its inhibition can suppress treatment-resistant lineage plasticity.

This study identifies Cu(DDC)2-alb as a dual agonist that enhances RAI uptake in thyroid cancer by stabilizing NIS and inducing thyroid transcription factors.

This study identifies RARγ's role in bookmarking AR enhancer interactions in prostate cancer, showing its impact on enzalutamide sensitivity and lineage plasticity.

This study shows that combining a novel ERβ ligand with Enzalutamide reduces MYC signaling and growth in advanced prostate cancer.

This study analyzes whole-exome sequencing data from Nigerian prostate cancer tumors to identify germline and somatic variants associated with African ancestry and DNA repair gene mutations.

This study identifies ARF4 and VCP as regulators of NIS trafficking and shows FDA-approved VCP inhibitors enhance radioiodine uptake in thyroid cancer cells and mice.